Occurrence Patterns of Bisphenol Analogues in Human Blood, Subcutaneous Fat, and Visceral Fat
Jiao P., Gao Y., Li A., Lu Z., Du M., Song J.
Laboratory Study, published in Environ Health (Wash) (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Environ Health (Wash) (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41562030
- PMCID
- PMC12813706
- DOI
- 10.1021/envhealth.5c00129
Abstract (original English)
Bisphenol analogues (BPs) are well-established endocrine-disrupting chemicals (EDCs). While they are generally not classified as persistent organic pollutants due to their relatively rapid metabolism and urinary excretion, a fraction can accumulate in tissues, including the adipose. This bioaccumulation raises concerns about the potential for prolonged endocrine disruption and chronic toxicity. This study investigated the distribution and accumulation of nine BPs in human blood, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT). By comparing the detection rates and concentrations of BPs in paired blood and adipose samples, we found that certain BPs (particularly BPF, BPE, and BPA-G) exhibit preferential accumulation in adipose tissues. The accumulation propensity was slightly higher in SAT than in VAT. Correlation analysis revealed that the sources of the same BP in VAT and SAT were highly consistent, whereas most BPs in adipose tissues had significantly different sources compared with those in blood. Further analysis suggested that age and obesity might be key factors influencing the differential accumulation of BPs in adipose tissues. Since accumulated BPs can be slowly or substantially released during lipolysis, our findings highlight that the adipose tissue reservoir of BPs may play an important role in their long-term toxic effects.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.